Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35196370

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2022 Jun 2
First author
Tam CS

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Jun 2;139(22):3229-3230. doi: 10.1182/blood.2022015963.
    note
    Source null
    related pmid
    35653166
    relationship
    Comment in

Authors and identifiers

  1. name
    Tam CS
    type
    Author
  2. name
    Allan JN
    type
    Author
  3. name
    Siddiqi T
    type
    Author
  4. name
    Kipps TJ
    type
    Author
  5. name
    Jacobs R
    type
    Author
  6. name
    Opat S
    type
    Author
  7. name
    Barr PM
    type
    Author
  8. name
    Tedeschi A
    type
    Author
  9. name
    Trentin L
    type
    Author
  10. name
    Bannerji R
    type
    Author
  11. name
    Jackson S
    type
    Author
  12. name
    Kuss BJ
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Tam CS
    type
    Author
  2. name
    Allan JN
    type
    Author
  3. name
    Siddiqi T
    type
    Author
  4. name
    Kipps TJ
    type
    Author
  5. name
    Jacobs R
    type
    Author
  6. name
    Opat S
    type
    Author
  7. name
    Barr PM
    type
    Author
  8. name
    Tedeschi A
    type
    Author
  9. name
    Trentin L
    type
    Author
  10. name
    Bannerji R
    type
    Author
  11. name
    Jackson S
    type
    Author
  12. name
    Kuss BJ
    type
    Author
bibliography ids
  1. nci-bib-3fa83d83206f776cc09f836c
book metadata
content sha256
cf86d58e91e6565c4968cf75caa3d2528414814a97af79f9e46728b9b04cc46e
document type
citation
dois
  1. 10.1182/blood.2021014488
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35196370
immutable id
pubmed:35196370@cf86d58e91e6565c4968cf75caa3d2528414814a97af79f9e46728b9b04cc46e
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
22
name
Blood
nlm unique id
7603509
pages
3278-3289
volume
139
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 Jun 2;139(22):3229-3230. doi: 10.1182/blood.2022015963.
    note
    Source null
    related pmid
    35653166
    relationship
    Comment in
outcomes validated
false
pmid
35196370
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
b5d59e1cc58221b0c9725730837491785b0c6ca30e077dd30274d893ed9ed8e3
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 Jun 2
precision
day
year
2022
publication types
  1. Journal Article
  2. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35196370/
title
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.

Preserved source evidence · Not medical advice